HPC Perspectives: Episode 6

Jul 30, 2024, 4:00 pm * The date/time is modified to match the user’s browser timezone.

ON-DEMAND viewing now available , Online

Category: Livestream

AI: The New Frontier of Drug Discovery

Embark on a journey through the cutting-edge world of drug discovery and artificial intelligence (AI) with Gemma and Natalia. Discover how data and AI are revolutionizing the pharmaceutical landscape, uncovering new insights, and propelling medical innovation forward.

Learn about the incredible potential of artificial (augmented) intelligence, ethical considerations, and the profound impact these advancements will have on patient outcomes. Join us as we unveil the future of medicine through the lens of data-driven discovery, high-performance computing, and the promise of AI.

**Please check your video quality is set to maximum by selecting the 'Settings' cog at the bottom of the video player, 'Quality' and '1080p'.**

Natalia Jimenez, PhD, Global Life Sciences Industry Lead, Viridien

Natalia is responsible for leading life sciences business development for Viridien's HPC & Cloud solutions. Natalia joined Viridien in August 2023, bringing with her over 25 years of experience in life sciences and technology, having worked for companies including Eviden and Atos. Natalia's roots are in biochemistry, molecular biology, and bioinformatics, having obtained her PhD at the National Center of Biotechnology that belongs to the Spanish Research Council. Outside of work, Natalia is mentor of the Welcome Genome Campus Startup School and the ELIXIR Leadership And Diversity mentoring program.

Gemma Holliday, Associate Principle Cheminformatician, AstraZeneca

Gemma joined AstraZeneca in 2023, having worked at the interface of chemistry and biology for over 20 years. Following her degree in Chemistry from the University of St Andrews, Gemma obtained a PhD in Cheminformatics from the University of Cambridge. After working for 6 years as a Research Scientist for the European Bioinformatics institute, Gemma relocated to the University of California, San Francisco and accepted a role as the Executive Director of the Structure-Function Link Database where she remained for 5 years before moving into industry as a Bioinformatics Data Scientist and Lead Cheminformatician for Medicines Discovery Catapult. Today, at AstraZeneca, Gemma is part of the team responsible for enabling the digitisation journey of the Pharmaceutical Sciences division. Outside of work, she enjoys tabletop roleplaying games, writing, the great outdoors and spending time with family, friends, and dogs.